Treatment of Inflammatory Bowel Disease with Biologics
93 of psoriasis and psoriatic arthritis (PsA) for several years. As such, there is still little evidence on the safety of the us ...
94 who resumed treatment with IFX following delivery, breast milk samples were obtained daily for up to 8 days post-IFX infusion ...
95 Ustekinumab Animal studies have confirmed the presence of UST in the milk of lactating mon- keys [ 80 ], which has been gener ...
96 Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during preg- nancy: in-hospital management and bi ...
97 Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in patients with Crohn’s disease: more than 5 ...
98 lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res. 2015;67:313–25. Colombel JF, Sand ...
99 Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy: effects on the neonatal immune system. Acta ...
© Springer International Publishing AG 2018 101 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
102 on treatment success [ 10 ], the use of high-dose steroids and recruitment of a popula- tion with a milder disease course an ...
103 when adding an immunosuppressive agent to adalimumab [ 20 ]. Within this second meta-analysis, an interesting observation wa ...
104 complications (HR 0.74, 95% CI 0.62–0.89) and surgeries (HR 0.68, 95% CI 0.49– 0.95) and the combined outcome of hospitaliza ...
105 the elderly (≥65 years) and those on chronic narcotics [ 6 , 28 , 30 , 31 ]. The exact mechanism through which narcotics in ...
106 therapy as a general rule of thumb appears to be most appropriate for IBD patients with extensive disease or those at risk f ...
107 therapy can be taken through modifying risk factors and thiopurine metabolite assess- ments [ 63 – 67 ] (Fig. 7.2). The trad ...
108 Future Considerations We have summarized the current evidence available to guide concomitant immunosuppressive use with TNF- ...
109 References Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab lev ...
110 Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of ant ...
111 Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile inf ...
112 Ben-Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibod ...
© Springer International Publishing AG 2018 113 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
«
1
2
3
4
5
6
7
8
9
10
»
Free download pdf